00018091222025-01-012025-06-300001809122cvac:BiontechSEMembercvac:CurevacNVMemberifrs-full:TopOfRangeMembersrt:ScenarioForecastMember2025-06-122025-06-120001809122cvac:BiontechSEMembercvac:CurevacNVMemberifrs-full:BottomOfRangeMembersrt:ScenarioForecastMember2025-06-122025-06-120001809122cvac:CrisprMember2025-04-012025-06-300001809122cvac:CrisprMember2025-01-012025-06-300001809122cvac:GlaxosmithklineMember2024-04-012024-06-300001809122cvac:CrisprMember2024-04-012024-06-300001809122cvac:GlaxosmithklineMember2024-01-012024-06-300001809122cvac:CrisprMember2024-01-012024-06-300001809122cvac:ResearchAndDevelopmentServicesMemberifrs-full:GoodsOrServicesTransferredOverTimeMember2025-04-012025-06-300001809122cvac:ResearchAndDevelopmentServicesCombinedWithIpLicenseMemberifrs-full:GoodsOrServicesTransferredOverTimeMember2025-04-012025-06-300001809122country:CHcvac:CrisprMember2025-04-012025-06-300001809122country:BEcvac:GlaxosmithklineMember2025-04-012025-06-300001809122ifrs-full:GoodsOrServicesTransferredOverTimeMember2025-04-012025-06-300001809122cvac:ResearchAndDevelopmentServicesMemberifrs-full:GoodsOrServicesTransferredOverTimeMember2025-01-012025-06-300001809122cvac:ResearchAndDevelopmentServicesCombinedWithIpLicenseMemberifrs-full:GoodsOrServicesTransferredOverTimeMember2025-01-012025-06-300001809122cvac:IfrsProductMemberifrs-full:GoodsOrServicesTransferredAtPointInTimeMember2025-01-012025-06-300001809122country:CHcvac:CrisprMember2025-01-012025-06-300001809122country:BEcvac:GlaxosmithklineMember2025-01-012025-06-300001809122ifrs-full:GoodsOrServicesTransferredOverTimeMember2025-01-012025-06-300001809122ifrs-full:GoodsOrServicesTransferredAtPointInTimeMember2025-01-012025-06-300001809122cvac:ResearchAndDevelopmentServicesMemberifrs-full:GoodsOrServicesTransferredOverTimeMember2024-04-012024-06-300001809122cvac:ResearchAndDevelopmentServicesCombinedWithIpLicenseMemberifrs-full:GoodsOrServicesTransferredOverTimeMember2024-04-012024-06-300001809122cvac:IfrsProductMemberifrs-full:GoodsOrServicesTransferredAtPointInTimeMember2024-04-012024-06-300001809122cvac:GlaxosmithklineMembercvac:ResearchAndDevelopmentServicesMember2024-04-012024-06-300001809122country:CHcvac:CrisprMember2024-04-012024-06-300001809122country:BEcvac:GlaxosmithklineMember2024-04-012024-06-300001809122ifrs-full:GoodsOrServicesTransferredOverTimeMember2024-04-012024-06-300001809122ifrs-full:GoodsOrServicesTransferredAtPointInTimeMember2024-04-012024-06-300001809122cvac:ResearchAndDevelopmentServicesMemberifrs-full:GoodsOrServicesTransferredOverTimeMember2024-01-012024-06-300001809122cvac:ResearchAndDevelopmentServicesCombinedWithIpLicenseMemberifrs-full:GoodsOrServicesTransferredOverTimeMember2024-01-012024-06-300001809122cvac:IfrsProductMemberifrs-full:GoodsOrServicesTransferredAtPointInTimeMember2024-01-012024-06-300001809122cvac:GlaxosmithklineMembercvac:ResearchAndDevelopmentServicesMember2024-01-012024-06-300001809122cvac:CollaborationAgreementForResearchDevelopmentManufacturingAndCommercializationOfMrnaBasedVaccinesMembercvac:GlaxosmithklineMember2024-01-012024-06-300001809122country:CHcvac:CrisprMember2024-01-012024-06-300001809122country:BEcvac:GlaxosmithklineMember2024-01-012024-06-300001809122ifrs-full:GoodsOrServicesTransferredOverTimeMember2024-01-012024-06-300001809122ifrs-full:GoodsOrServicesTransferredAtPointInTimeMember2024-01-012024-06-300001809122cvac:BiontechSEMembercvac:CurevacNVMembersrt:ScenarioForecastMember2025-06-122025-06-120001809122ifrs-full:PreferenceSharesMember2025-06-300001809122ifrs-full:OrdinarySharesMember2025-06-300001809122ifrs-full:ShareOptionsMembercvac:SupervisoryBoardMembersMember2025-02-242025-02-240001809122ifrs-full:ShareOptionsMembercvac:MembersOfExecutiveBoardAndVariousKeyEmployeesMember2025-02-242025-02-240001809122ifrs-full:ShareOptionsMembercvac:KeyEmployeesMember2025-01-012025-01-010001809122cvac:SellingAndDistributionExpensesMember2025-04-012025-06-300001809122cvac:OtherOperatingExpensesMember2025-04-012025-06-300001809122cvac:SellingAndDistributionExpensesMember2025-01-012025-06-300001809122cvac:OtherOperatingExpensesMember2025-01-012025-06-300001809122cvac:SellingAndDistributionExpensesMember2024-04-012024-06-300001809122cvac:OtherOperatingExpensesMember2024-04-012024-06-300001809122cvac:SellingAndDistributionExpensesMember2024-01-012024-06-300001809122cvac:OtherOperatingExpensesMember2024-01-012024-06-300001809122ifrs-full:RetainedEarningsMember2025-06-300001809122ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2025-06-300001809122ifrs-full:IssuedCapitalMember2025-06-300001809122ifrs-full:CapitalReserveMember2025-06-300001809122ifrs-full:RetainedEarningsMember2024-12-310001809122ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2024-12-310001809122ifrs-full:IssuedCapitalMember2024-12-310001809122ifrs-full:CapitalReserveMember2024-12-310001809122ifrs-full:RetainedEarningsMember2024-06-300001809122ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2024-06-300001809122ifrs-full:IssuedCapitalMember2024-06-300001809122ifrs-full:CapitalReserveMember2024-06-300001809122ifrs-full:RetainedEarningsMember2023-12-310001809122ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2023-12-310001809122ifrs-full:IssuedCapitalMember2023-12-310001809122ifrs-full:CapitalReserveMember2023-12-310001809122cvac:MembersOfExecutiveBoardAndVariousKeyEmployeesMember2025-01-012025-06-300001809122cvac:KeyEmployeesMember2025-01-012025-06-300001809122ifrs-full:RetainedEarningsMember2025-01-012025-06-300001809122ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2025-01-012025-06-300001809122ifrs-full:RetainedEarningsMember2024-01-012024-06-300001809122ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2024-01-012024-06-300001809122cvac:CurevacNVMember2025-08-310001809122cvac:LongTermIncentivePlanMembercvac:MembersOfExecutiveBoardAndVariousKeyEmployeesMember2025-02-242025-02-240001809122cvac:LongTermIncentivePlanMembercvac:KeyEmployeesMember2025-01-012025-01-010001809122cvac:GlaxosmithklineMember2025-06-300001809122cvac:CrisprMember2025-06-3000018091222020-11-302020-11-3000018091222025-01-012025-03-3100018091222024-01-012024-03-310001809122ifrs-full:IssuedCapitalMember2025-01-012025-06-300001809122ifrs-full:IssuedCapitalMember2024-01-012024-06-300001809122cvac:GlaxosmithklineMember2025-08-310001809122ifrs-full:CapitalReserveMember2025-01-012025-06-300001809122ifrs-full:CapitalReserveMember2024-01-012024-06-300001809122ifrs-full:CostOfSalesMember2025-04-012025-06-300001809122ifrs-full:CostOfSalesMember2025-01-012025-06-300001809122cvac:LargestShareholderMember2025-06-300001809122cvac:GlaxosmithklineMember2025-08-012025-08-310001809122cvac:CurevacNVMember2025-08-012025-08-310001809122ifrs-full:LegalProceedingsProvisionMember2024-07-012024-07-310001809122ifrs-full:LegalProceedingsProvisionMember2024-05-012024-05-310001809122cvac:BiontechSEMember2025-06-1200018091222025-06-1200018091222020-11-300001809122cvac:BiontechSEMembercvac:CurevacNVMembersrt:ScenarioForecastMember2025-06-120001809122cvac:IfrsResearchAndDevelopmentExpenseMember2025-04-012025-06-300001809122cvac:IfrsGeneralAndAdministrativeExpenseMember2025-04-012025-06-300001809122cvac:IfrsResearchAndDevelopmentExpenseMember2025-01-012025-06-300001809122cvac:IfrsGeneralAndAdministrativeExpenseMember2025-01-012025-06-300001809122ifrs-full:CostOfSalesMember2024-04-012024-06-300001809122cvac:IfrsResearchAndDevelopmentExpenseMember2024-04-012024-06-300001809122cvac:IfrsGeneralAndAdministrativeExpenseMember2024-04-012024-06-300001809122ifrs-full:CostOfSalesMember2024-01-012024-06-300001809122cvac:IfrsResearchAndDevelopmentExpenseMember2024-01-012024-06-300001809122cvac:IfrsGeneralAndAdministrativeExpenseMember2024-01-012024-06-3000018091222024-01-012024-12-310001809122cvac:BiontechSEMembercvac:CurevacNVMemberdei:AdrMembersrt:ScenarioForecastMember2025-06-120001809122ifrs-full:ShareOptionsMember2025-04-012025-06-300001809122cvac:RsuSupervisoryBoardMember2025-04-012025-06-300001809122cvac:LongTermIncentivePlanAndRestrictedStockUnitMember2025-04-012025-06-3000018091222025-04-012025-06-300001809122ifrs-full:ShareOptionsMember2025-01-012025-06-300001809122cvac:RsuSupervisoryBoardMember2025-01-012025-06-300001809122cvac:LongTermIncentivePlanAndRestrictedStockUnitMember2025-01-012025-06-300001809122ifrs-full:ShareOptionsMember2024-04-012024-06-300001809122cvac:RsuSupervisoryBoardMember2024-04-012024-06-300001809122cvac:PriorVirtualStockOptionsPlanMember2024-04-012024-06-300001809122cvac:LongTermIncentivePlanAndRestrictedStockUnitMember2024-04-012024-06-3000018091222024-04-012024-06-300001809122ifrs-full:ShareOptionsMember2024-01-012024-06-300001809122cvac:RsuSupervisoryBoardMember2024-01-012024-06-300001809122cvac:PriorVirtualStockOptionsPlanMember2024-01-012024-06-300001809122cvac:LongTermIncentivePlanAndRestrictedStockUnitMember2024-01-012024-06-3000018091222025-06-3000018091222025-03-3100018091222024-12-3100018091222024-06-3000018091222024-03-3100018091222023-12-310001809122cvac:CurevacNVMember2025-06-120001809122ifrs-full:LegalProceedingsProvisionMember2024-01-012024-06-3000018091222024-01-012024-06-30iso4217:EURiso4217:USDxbrli:sharesiso4217:USDxbrli:sharesxbrli:purecvac:itemiso4217:EURxbrli:sharescvac:Ycvac:Option
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF THE
SECURITIES EXCHANGE ACT OF 1934
For the month of August 2025
Commission File Number: 001-39446
CureVac N.V.
(Exact Name of Registrant as Specified in Its Charter)
Friedrich-Miescher-Strasse 15, 72076
Tübingen, Germany
+49 7071 9883 0
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
This Report of Foreign Private Issuer on Form 6-K (this “Form 6-K”) is being furnished by CureVac N.V. (“CureVac”) to the Securities and Exchange Commission (the “SEC”) for the sole purposes of: (i) furnishing, as Exhibit 99.1 to this Form 6-K, Unaudited Interim Condensed Consolidated Financial Statements announcing CureVac’s financial results and business updates as of June 30, and for the three and six months ended June 30, 2025 and 2024; and (ii) furnishing, as Exhibit 99.2 to this Form 6-K, Management’s Discussion and Analysis of Financial Condition and Results of Operations, which discusses and analyzes CureVac’s financial condition and results of operations as of June 30, 2025 and for the six month periods ended June 30, 2025 and 2024.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| | | |
CUREVAC N.V. | | |
| | | |
By: | /s/Axel Sven Malkomes | | By: | /s/Alexander Zehnder |
| Chief Financial Officer | | | Chief Executive Officer |
| | | |
| | | |
Date: August 15, 2025 | | | |
EXHIBIT INDEX
EXHIBIT NO. | | DESCRIPTION |
99.1 | | Unaudited Interim Condensed Consolidated Financial Statements as of June 30, 2025 and for the three and six months ended June 30, 2025 and 2024 |
99.2 | | Management’s Discussion and Analysis of Financial Condition and Results of Operations |
